Literature DB >> 18805101

Disparities in use of same-day percutaneous coronary intervention for patients with ST-elevation myocardial infarction in Florida, 2001-2005.

Elizabeth Barnett Pathak1, Joel A Strom.   

Abstract

Primary percutaneous coronary intervention (PCI) is the recommended treatment for ST-elevation myocardial infarction (STEMI), according to American College of Cardiology and American Heart Association guidelines published in 1999 and 2004. In this study, hospital and patient predictors of same-day primary PCI use for STEMI were examined across the period from 2001 to 2005. Inpatient discharge data for adults aged > or =18 years with primary diagnoses of STEMI who were admitted to Florida hospitals through emergency departments (ED) from 2001 to 2005 (n = 58,308) were analyzed. Hierarchical (multilevel) logistic regression models were used to assess hospital PCI volume and individual characteristics as predictors of same-day PCI use for patients at PCI-capable hospitals. The percentage of ED-admitted patients with a STEMI who received same-day PCI in Florida increased from 20% in early 2001 to 43% in late 2005. At PCI-capable hospitals, 50% of these patients received same-day PCI in late 2005. Patients admitted on weekends, women, patients aged > or = 75 years, patients with chronic obstructive pulmonary disease, and patients with end-stage renal disease were all significantly less likely to receive same-day PCI. Black patients were less likely to receive same-day PCI in early 2001 (adjusted odds ratio [OR] 0.7, 95% confidence interval 0.5 to 0.9, p <0.0001), but this racial disparity was not evident by late 2005 (adjusted OR 1.0). Men were more likely than women to receive same-day PCI, with a significant association remaining in late 2005 (adjusted OR 1.2, 95% confidence interval 1.1 to 1.4, p <0.0001). Throughout the study period, the strongest predictor of same-day PCI was admission to a high- or medium-volume PCI-capable hospital; the adjusted OR in late 2005 was 4.6 (95% confidence interval 2.8 to 7.6, p <0.0001). In conclusion, weekend admission, female gender, older age, and serious co-morbidities were all significant barriers to receiving same-day PCI. Among patients admitted to PCI-capable hospitals, total PCI volume (high or medium vs low) was associated with significantly greater odds of receiving primary PCI, independent of patient sociodemographics, risk factors, or co-morbidities. Statewide, despite an increase in the use of PCI over time, most ED-admitted patients with a STEMI in Florida did not receive primary PCI in late 2005.

Entities:  

Mesh:

Year:  2008        PMID: 18805101     DOI: 10.1016/j.amjcard.2008.05.023

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Changing Trends in, and Characteristics Associated with, Not Undergoing Cardiac Catheterization in Elderly Adults Hospitalized with ST-Segment Elevation Acute Myocardial Infarction.

Authors:  Mayra Tisminetzky; Nathaniel Erskine; Han-Yang Chen; Joel Gore; Jerry Gurwitz; Jorge Yarzebski; Samuel Joffe; Peter Shaw; Robert Goldberg
Journal:  J Am Geriatr Soc       Date:  2015-05-04       Impact factor: 5.562

Review 2.  Examining sex and gender disparities in total joint arthroplasty.

Authors:  Wendy M Novicoff; Khaled J Saleh
Journal:  Clin Orthop Relat Res       Date:  2011-07       Impact factor: 4.176

Review 3.  Off-hour presentation and outcomes in patients with acute myocardial infarction: systematic review and meta-analysis.

Authors:  Atsushi Sorita; Adil Ahmed; Stephanie R Starr; Kristine M Thompson; Darcy A Reed; Larry Prokop; Nilay D Shah; M Hassan Murad; Henry H Ting
Journal:  BMJ       Date:  2014-01-21

4.  Racial Difference in Symptom Onset to Door Time in ST Elevation Myocardial Infarction.

Authors:  Oluwaseyi Bolorunduro; Blake Smith; Mason Chumpia; Poojitha Valasareddy; Mark R Heckle; Rami N Khouzam; Guy L Reed; Uzoma N Ibebuogu
Journal:  J Am Heart Assoc       Date:  2016-09-30       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.